<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467334</url>
  </required_header>
  <id_info>
    <org_study_id>P040</org_study_id>
    <nct_id>NCT03467334</nct_id>
  </id_info>
  <brief_title>Infant Colic Treatment With Probiotics</brief_title>
  <official_title>Nutritional Intervention, Multicenter, Randomized, Blind, Parallel Groups Study to Assess the Effect of Consumption of Bifidobacterium Breve CECT7263 and Lactobacillus Fermentum CECT5716 on Infant Colic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mónica Olivares Martín</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Regional Development Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Ciencia e Innovación, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biosearch S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of Bifidobacterium breve CECT7263 and the mixture B. breve
      CECT7263/Lactobacillus fermentum CECT5716 in the treatment of infant colic. Group 1 will
      receive B. breve CECT7263 (2x10E8 CFU/day) one dose per day, group 2 will receive B. breve
      CECT7263 (1x10E8 CFU/day) and L. fermentum CECT5716 (1x10E8 CFU/day) in one dose per day,
      group 3 (control group) will receive simethicone 20 mg 4 times a day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infant colic affects between 3-40% depending on the different criteria used for diagnosis.
      Recent studies carried out in healthy infants have shown that the consumption of B. breve
      CECT7263 and L. fermentum CECT5716 during the first months of life are related to a lower
      risk to present episodes of crying characteristic of infantile colic.

      The objective of the present study is to compare the effect of B. brevis and B. brevis\L
      mixture. fermentum with respect to simethicone.

      It is a multicenter, controlled, randomized, blind, parallel-group, 4-weeks nutritional
      intervention study which will be conducted in 18 public and private hospitals and health
      centers from Spain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">January 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The control group is the usual treatment that is administered differently (oral drops, 4 times a day) to the 2 research treatments (powder, 1 time a day).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Crying time</measure>
    <time_frame>4 weeks</time_frame>
    <description>Crying time in minutes per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responders to treatment on weeks 1, 2, 3 and 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of responders to the treatment in each group on weeks 1, 2, 3 and 4. It is understood that responders are those infants who have experienced a daily decrease in the duration of the crises cries 50% above baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>4 weeks</time_frame>
    <description>Effect of the treatment on intestinal microbiota: the levels of Escherichia coli, Clostridium, Bacteroides, Lactobacillus and Bifidobacterium at the beginning and at the end of the study (weeks 0 and 4) will be analyzed by quantitative PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool carbohydrates</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stool carbohydrate levels: lactose and other carbohydrate levels will be analyzed by chromatography (Triple Quad LC/MS) at the beginning and end of the study (weeks 0 and 4).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Infant Colic</condition>
  <arm_group>
    <arm_group_label>B. breve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. breve plus L. fermentum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simethicone 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group that will receive simethicone 4 times (10 drops) a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>B. breve</intervention_name>
    <description>Bifidobacterium probiotic strain at 1E+08 cfu/day</description>
    <arm_group_label>B. breve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>B. breve plus L. fermentum</intervention_name>
    <description>Probiotic combination at 2E+08 cfu/day</description>
    <arm_group_label>B. breve plus L. fermentum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simethicone 20 MG</intervention_name>
    <description>Standard treatment for infant colic</description>
    <arm_group_label>Simethicone 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants from 3 to 12 weeks of age

          -  Born at least at week 34

          -  Birth weight equal to or greater than 2000 grams

          -  Fulfill the criteria of Rome III

          -  Informed consent signed by parents or guardians

        Exclusion Criteria:

          -  Failure to thrive

          -  Antibiotic treatment less than 2 weeks before the study or during the study

          -  Take probiotics as a treatment, different from the one that could contain the powdered
             infant formula

          -  Abandon breastfeeding and switch to infant formula

          -  Failure to comply with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Maldonado, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Specialist in Pediatrics of the Medical-Surgical UGC of Infancy of the University Hospital Complex of Granada (Spain)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juristo Fonollá, PhD</last_name>
    <phone>+34958240288</phone>
    <email>Juristo.FonollaJoya@biosearchlife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Servicio Andaluz de Salud</name>
      <address>
        <city>Granada</city>
        <zip>10012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Maldonado, MD/PhD</last_name>
      <phone>34958020124</phone>
      <email>jmaldon@ugr.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Biosearch S.A.</investigator_affiliation>
    <investigator_full_name>Mónica Olivares Martín</investigator_full_name>
    <investigator_title>Head of the R &amp; D Department</investigator_title>
  </responsible_party>
  <keyword>Infant colic</keyword>
  <keyword>Bifidobacterium breve</keyword>
  <keyword>Lactobacillus fermentum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simethicone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

